Search

ASCO 2021 recap: Lynparza's lift, Grail goes on, LAG validation & more

ASCO 2021 RECAP: LYNPARZA'S LIFT, GRAIL GOES ON, LAG VALIDATION & MORE

The American Society of Clinical Oncology' annual meeting featured news highlights from the Merck, Novartis, and other drug giants....

Pioneering a new realm of biology, startup Senda Bio expands financing to $98M

PIONEERING A NEW REALM OF BIOLOGY, STARTUP SENDA BIO EXPANDS FINANCING TO $98M

Senda Biosciences is developing drugs based on an understanding of intersystems biology-the way that humans interact with bacteria...

 
 
 
AI-drug discovery biotech Valo Health is going public via a $2.8B SPAC merger

AI-DRUG DISCOVERY BIOTECH VALO HEALTH IS GOING PUBLIC VIA A $2.8B SPAC MERGER

Valo Health is going public in a SPAC merger. Less than nine months removed from its formal launch, Valo is now revealing more about...

FARO HEALTH INC. SECURES $15 MILLION SERIES A FINANCING TO DELIVER DIGITAL TRANSFORMATION FOR CLINICAL STUDY DESIGN AND AUTHORING

SAN DIEGO: SAN DIEGO, June 8, 2021 /PRNewswire/ - Faro Health Inc., a cloud-computing company that simplifies the design and authoring...

 
 
 
FDA picks accelerated approval path to decide in favor of Biogen Alzheimer's drug

FDA PICKS ACCELERATED APPROVAL PATH TO DECIDE IN FAVOR OF BIOGEN ALZHEIMER'S DRUG

A Biogen Alzheimer's drug that clears amyloid plaque from the brain has been granted accelerated approved by the FDA. The drug, which...

At INVEST Precision Medicine, a look at the software behind biopharma R&D

AT INVEST PRECISION MEDICINE, A LOOK AT THE SOFTWARE BEHIND BIOPHARMA R&D

The conference, set for June 9-11, will explore different aspects of precision medicine, including the software being used to support...

 
 
 
Merus eyes tumor-agnostic path for cancer drug addressing rare genetic target

MERUS EYES TUMOR-AGNOSTIC PATH FOR CANCER DRUG ADDRESSING RARE GENETIC TARGET

Cancer drug developer Merus has encouraging early results indicating its drug can address several different types of tumors characterized...

Versant Ventures unveils new startup that stabilizes proteins to treat disease

VERSANT VENTURES UNVEILS NEW STARTUP THAT STABILIZES PROTEINS TO TREAT DISEASE

Stablix Therapeutics is developing technology that uses small molecules to stabilize a protein, keeping it from going to a cell's built-in...

 
 
 
Novartis radiopharmaceutical improves survival in key prostate cancer study

NOVARTIS RADIOPHARMACEUTICAL IMPROVES SURVIVAL IN KEY PROSTATE CANCER STUDY

Novartis reported Phase 3 study results for a targeted radiation therapy showing that treatment helped patients with advanced prostate...

Scynexis antifungal drug secures FDA nod; first approval in new class in 20 years

SCYNEXIS ANTIFUNGAL DRUG SECURES FDA NOD; FIRST APPROVAL IN NEW CLASS IN 20 YEARS

The FDA has approved Brexafemme, a Scynexis antifungal drug, for treating vaginal yeast infections. The drug is the biotech's first...

 
 
 

FIVE MORE BIOTECHS FILE THEIR SEC PAPERWORK AS THE IPO CLASS OF 2021 SWELLS TO 60

Editor's note: Interested in following biopharma's fast-paced IPO market? You can bookmark our IPO Tracker here. After last week's...

SCIENTIST/SR SCIENTIST - 48HD BIOPHARMA - SAN DIEGO, CA

Founded in 2017, 48Hour Discovery is a Canadian biotechnology company with headquarters in Edmonton, Alberta, and satellite sites in...

 
 
 
Amgen lands first FDA approval for drug targeting elusive mutation in lung cancer

AMGEN LANDS FIRST FDA APPROVAL FOR DRUG TARGETING ELUSIVE MUTATION IN LUNG CANCER

FDA approval of Amgen drug sotorasib makes the small molecule the first compound authorized by the regulator for treating cancers characterized...

WITH TWO DEBUTS AND A SPAC, BIOPHARMA NOTCHES ANOTHER BUSY WEEK AS IPO RAISE SOARS PAST $7B

Editor's note: Interested in following biopharma's fast-paced IPO market? You can bookmark our IPO Tracker here. After a slight lull...

 
 
 
Widespread EHR adoption provides rich source of patient data for Covid-19 research

WIDESPREAD EHR ADOPTION PROVIDES RICH SOURCE OF PATIENT DATA FOR COVID-19 RESEARCH

Data captured in EHR systems provide near real-time information about the nationwide vaccine rollout, help monitor potential safety...

Engine Biosciences revs up $43M for AI tech that yields targeted cancer therapies

ENGINE BIOSCIENCES REVS UP $43M FOR AI TECH THAT YIELDS TARGETED CANCER THERAPIES

Engine Biosciences closed a $43 million Series A financing that the startup will apply to its artificial intelligence-based technology...

 
 
 

BOCA BIOLISTICS IS THE FIRST CRO TO PARTICIPATE IN VERIF.I®, SCIENTIST'S NEW SUPPLIER PRE-ASSESSMENT PROGRAM

SAN DIEGO-- biopharma-With completion of an on-site assessment, Boca Biolistics is 1st CRO to participate in VERIF.i®, Scientist.com's...

NGM Bio's NASH drug fails in Phase 2; focus shifts to Merck-partnered programs

NGM BIO'S NASH DRUG FAILS IN PHASE 2; FOCUS SHIFTS TO MERCK-PARTNERED PROGRAMS

An NGM Biopharmaceuticals drug candidate for the fatty liver disease NASH failed a Phase 2b study less than a year after the company...

 
 
 
CVS joins the decentralized clinical trials movement with launch of new biz unit

CVS JOINS THE DECENTRALIZED CLINICAL TRIALS MOVEMENT WITH LAUNCH OF NEW BIZ UNIT

CVS has launched a new clinical trials services business that will help drug companies and contract research organizations recruit...

Eli Lilly looks ahead to FDA after diabetes drug wraps up last clinical test

ELI LILLY LOOKS AHEAD TO FDA AFTER DIABETES DRUG WRAPS UP LAST CLINICAL TEST

Eli Lilly diabetes drug tirzepatide beat long-acting insulin in the last of a series of global studies designed to support regulatory...